In 1951 he received a supply of CPZ for his clinical

investigations. In February 1952 Laborit, in collaboration with Huguenard and Alluaume, reported that in doses of 50 to 100 mg intravenously, CPZ does not cause loss of consciousness or any change in the patient’s mentation, but produces a, tendency to sleep and disinterest in the surroundings.57 In the same report Laborit recognized the potential use of CPZ in psychiatry.59 The first use of Inhibitors,research,lifescience,medical CPZ in a psychiatric patient was reported by Hamon, Paraire, and Velluz, at. Val de Grace, the military hospital in Paris, in March 1952, about a, month after the report of Laborit.60 NVP-BEZ235 in vitro Before the end of the year there were several other reports, including the six papers by Delay and Deniker from the Saint, Anne Hospital in Paris that set the stage for CPZ’s development in psychiatry; there followed a, report, on the

successful treatment of an aggressive paranoid patient by Follin, at Montauban Mental Hospital, in Inhibitors,research,lifescience,medical France, and an article on 20 psychiatric patients treated with CPZ, by Rigotti, in Padua, Italy. CPZ became available on prescription in France in November 1952 under the trade name of Largact.il. Subsequently, within a short, period of 3 years, from 1953 to 1955, CPZ treatment Inhibitors,research,lifescience,medical in psychiatry spread around the world.54,61 The first international colloquium on the therapeutic uses of CPZ in psychiatry was held in Paris, in October, 1955, with 257 participants Inhibitors,research,lifescience,medical from 15 countries.62The importance of CPZ was recognized by the scientific community in 1957 with the presentation of the American Public Health Association’s prestigious Albert Lasker Award to the three key players in the clinical development of the drug: Henri Laborit, for first using CPZ as a therapeutic agent and recognizing its potential for psychiatry; Pierre Deniker, Inhibitors,research,lifescience,medical for his leading role in introducing CPZ into psychiatry and demonstrating its influence on the clinical course of psychosis; and Heinz E. Lehmann, from Canada, for bringing the full practical significance of CPZ to the attention of the

medical community. In the same year Daniel Bovet was awarded the Nobel Prize in Medicine for his major contributions to the synthesis of antihistamines which, to through Laborit’s serendipitious discovery that an antihistaminic phenothiazine, promethazine, produced a, state of detachment and indifference, led to the development of CPZ.63 Imipramine TTtic serendipitous discovery of the therapeutic effect of imipramine in depression was the result of search for a CPZ-like substance for the treatment, of schizophrenia by Geigy, at the time a major Swiss pharmaceutical company. The discovery is linked to the name of Roland Kuhn, a Swiss psychiatrist, working at, the cantonal mental hospital of Münsterlingen.